pharmacies must stop selling compounded semaglutide after may 2025 Drugmakers battle over Ozempic and Zepbound : Shots Compounding pharmacies to halt semaglutide

Morris AE, Schmid J

Recent advances in severe asthma: From phenotypes to personalized medicine

lfod14 2024-08-22 21:01:01 UTC #6 From playing with the dosages a lot over the last year or two, seems the 0.25mg is pretty much the lowest dose where you can actually notice it working, you can adapt pretty quickly, especially if you follow the dosage guidelines, but for appetite suppression, you definitely dont need to ramp the dose up like youre supposed to, for a while when I upd to 0.25mg/2xwk which kept the suppression down better after I originally adapted

What Youll Learn: What GLP-1s (Ozempic, Wegovy, Mounjaro, etc.) are, how they work, and what the current evidence shows The potential benefits and risks - medical, psychological, and social Questions of access, equity, stigma, and the cultural narratives surrounding weight What we know (and dont yet know) about the long-term outlook and what comes after GLP-1s How to make or support informed, autonomous decisions about treatment options Whats Included in This Digital Bundle: 2.5-hours video recording presentation slides Printable note-taking materials Private access to a dedicated course page Lifetime access return anytime, learn at your own pace Certificate of Attendance (issued after feedback form submission) Who Its For: This course is designed for anyone interested in understanding GLP-1s from individuals thinking about starting the journey, to those supporting loved ones, to professionals in health and wellbeing fields

The role of GLP-1-based receptor agonists (RAs) GLP-1-based RAs are a class of medications used primarily to treat T2DM and obesity